Biotech Startups
9,911 companies tagged Biotech, with their investors and founders.
Aloe Therapeutics develops AIM-001, a localized cell-based immunotherapy implanted at tumor sites during surgery to activate the immune system and improve response to checkpoint immunotherapy in patients with advanced solid tumors.
2 investors
Alpha Tau Medical develops Alpha DaRT, a technology platform for cancer treatment using targeted alpha radiation therapy across multiple cancer types including skin, pancreatic, brain, lung, and prostate cancers at various clinical stages.
2 investors
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision. It operates in the oncology and precision medicine space.
2 investors
Alphabiome builds an AI layer for drug development that analyzes raw bacterial, viral, and host DNA lacking a reference map to predict which therapies work in which patients. Its technology is applied to precision medicine, spanning multiple indications and therapies.
2 investors
AlphaNavi Pharma is a pharmaceutical company developing new drugs (Nav channel inhibitors) for patients suffering from chronic pain and neurological disorders. It conducts in-house research and development in collaboration with academia, companies, and investors in Japan and abroad.
2 investors
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMAβ’), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites. The company's lead program is in a randomized Phase 2b trial for newly diagnosed glioblastoma.
2 investors
2 investors
Altasciences operates a drug development platform that integrates nonclinical research, bioanalysis, manufacturing, and Phase I/II clinical execution to compress early-stage drug development timelines from industry standards of 27β51 months to as little as 18 months. The company serves biotech sponsors developing small molecules, monoclonal antibodies, and emerging modalities through parallel workstreams across all development phases.
2 investors
2 investors
Amass operates an agentic data platform that unifies over 500 million scientific documents β including research literature, patents, clinical trials, regulatory filings, and web sources β into a single engine that returns answers cited to their source. It serves researchers, life science companies, and research institutions through an app, API, and MCP interface, with each claim traceable to underlying evidence.
2 investors
Ambrosia Bio produces rare sugars such as Allulose as low- to no-calorie replacements for sugar, offering a similar taste, sweetness, and textural profile without artificial aftertaste. Its portfolio is intended for food producers seeking sugar alternatives and is stated to be safe for diabetic use.
2 investors
Amferia develops antimicrobial hydrogel wound dressings that kill bacteria including antibiotic-resistant strains using peptides bonded to hydrogel, for human and veterinary wound care applications. The company's patented technology creates a new class of medical device approved by the FDA for advanced wound management.
2 investors
Amgen develops therapies based on biotechnology and scientific research aimed at treating patients and improving or saving lives. It operates in the biopharmaceutical industry, moving discoveries from the laboratory through clinical development to market.
2 investors
AmphiStar develops biosurfactants through advanced bioprocessing and fermentation for industrial applications including chemicals and consumer goods. The company focuses on bio-based alternatives to conventional surfactants, serving industries seeking sustainable biochemical solutions.
2 investors
AmplifiDx develops point-of-care molecular diagnostic tests and its DX 100 platform for family, women's, and sexual health, targeting infectious disease detection for healthcare professionals and patients. The multiplex platform can detect up to 10 analytes with rapid results and minimal hands-on time.
2 investors
AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications. The company develops biomarker discovery tools and clinical research solutions for clinicians and researchers to enable earlier disease detection and targeted interventions.
2 investors
AMS develops next-generation nuclear medicine technologies for Japan's market, including PET diagnostics and radiotherapeutics for precision oncology, alongside a proprietary bedside filtration system for safe radioactive waste management in hospitals.
2 investors
Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.
2 investors
Amyriad Therapeutics develops disease-modifying therapies for Alzheimer's disease, with a lead candidate called Ismidenon that employs novel cholinergic enhancement mechanisms. The company is led by neuroscientists and clinical experts focused on restoring cognitive function in aging-related neurodegeneration.
2 investors
Amyris develops a biomanufacturing platform that uses fermentation and microbial engineering to produce natural ingredients and rare compounds at scale for partners across industries such as specialty chemicals, food ingredients, and consumer products. Founded in 2003, the company focuses on sustainable, bio-based sourcing of molecules.
2 investors
AnaBios generates predictive human data for pharmaceutical drug development, using authentic human cells and tissues from healthy and diseased donors to assess drug efficacy and toxicity before clinical trials. It offers human tissue procurement and functional assay services, including gene expression, proteomic, and metabolomic profiling, to support drug discovery and preclinical safety testing.
2 investors
Anaconda Biomed develops next-generation endovascular access and protection devices. The company serves the medical device market, focusing on vascular intervention procedures.
2 investors
AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders. It is a publicly traded biotech company running with fewer than ~10 contractors.
2 investors
AnchorDx develops, manufactures, and sells cancer early-screening and diagnostic products based on ctDNA methylation high-throughput sequencing, along with related testing services covering over 70% of high-incidence cancers such as lung, breast, digestive, and urinary cancers. Founded in 2015 in Guangzhou, China with R&D centers in China and the US, it also runs a big-data and AI platform focused on lung cancer detection and treatment.
2 investors